journal article·2024-03Open access

A biomaterial platform for T cell-specific gene delivery

Sharda Pandit, Blake E. Smith, Michael E. Birnbaum, Yevgeny Brudno

Acta Biomaterialia· Volume 177

Abstract

Efficient T cell engineering is central to the success of CAR T cell therapy but involves multiple time-consuming manipulations, including T cell isolation, activation, and transduction. These steps add complexity and delay CAR T cell manufacturing, which takes a mean time of 4 weeks. To streamline T cell engineering, we strategically combine two critical engineering solutions - T cell-specific lentiviral vectors and macroporous scaffolds - that enable T cell activation and transduction in a simple, single step. The T cell-specific lentiviral vectors (referred to as STAT virus) target T cells through the display of an anti-CD3 antibody and the CD80 extracellular domain on their surface and provide robust T cell activation. Biocompatible macroporous scaffolds (referred to as Drydux) mediate robust transduction by providing effective interaction between naïve T cells and viral vectors. We show that when unstimulated peripheral blood mononuclear cells (PBMCs) are seeded together with STAT lentivirus on Drydux scaffolds, T cells are activated, selectively transduced, and reprogrammed in a single step. Further, we show that the Drydux platform seeded with PBMCs and STAT lentivirus generates tumor-specific functional CAR T cells. This potent combination of engineered lentivirus and biomaterial scaffold holds promise for an effective, simple, and safe avenue for in vitro and in vivo T cell engineering. STATEMENT OF SIGNIFICANCE: Manufacturing T cell therapies involves lengthy and labor-intensive steps, including T cell selection, activation, and transduction. These steps add complexity to current CAR T cell manufacturing protocols and limit widespread patient access to this revolutionary therapy. In this work, we demonstrate the combination of engineered virus and biomaterial platform that, together, enables selective T cell activation and transduction in a single step, eliminating multistep T cell engineering protocols and significantly simplifying the manufacturing process.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: CAR-T cell therapy research · Virus-based gene therapy research · Nanowire Synthesis and Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (42)

Show source-provided references
1. Systematic review of available CAR-T cell trials around the world10.3390/cancers14112667 ↗
2. CAR-T cell therapy: current limitations and potential strategies10.1038/s41408-021-00459-7 ↗
3. Engineering strategies to overcome the current roadblocks in CAR T cell therapy10.1038/s41571-019-0297-y ↗
4. Clinical manufacturing of CAR T cells: foundation of a promising therapy10.1038/mto.2016.15 ↗
5. Value and affordability of CAR T-cell therapy in the United States10.1038/s41409-020-0956-8 ↗
6. Early-phenotype CAR-T cells for the treatment of pediatric cancers10.1016/j.annonc.2021.07.018 ↗
7. Chimeric antigen receptor T cell therapy for solid tumors: current status, obstacles and future strategies10.3390/cancers11020191 ↗
8. CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment10.3389/fimmu.2019.00128 ↗
9. Optimizing manufacturing protocols of chimeric antigen receptor T cells for improved anticancer immunotherapy10.3390/ijms20246223 ↗
10. A novel autologous CAR-T therapy, YTB323, with preserved T-cell stemness shows enhanced CAR T-cell efficacy in preclinical and early clinical development10.1158/2159-8290.CD-22-1276 ↗
11. Choosing the right tool for genetic engineering: clinical lessons from chimeric antigen receptor-T cells10.1089/hum.2021.173 ↗
12. Engineering targeted viral vectors for gene therapy10.1038/nrg2141 ↗
13. Lentiviral vectors for T cell engineering: clinical applications, bioprocessing and future perspectives10.3390/v13081528 ↗
14. LDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virus10.1073/pnas.1214441110 ↗
15. Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell10.1038/s41591-018-0201-9 ↗
16. Mystery solved: VSV-G-LVs do not allow efficient gene transfer into unstimulated T cells, B cells, and HSCs because they lack the LDL receptor10.1182/blood-2013-11-540641 ↗
17. Combining T-cell-specific activation and in vivo gene delivery through CD3-targeted lentiviral vectors
18. Antigen identification and high-throughput interaction mapping by reprogramming viral entry10.1038/s41592-022-01436-z ↗
19. Cell type-specific targeting with surface-engineered lentiviral vectors co-displaying OKT3 antibody and fusogenic molecule10.1007/s11095-009-9853-y ↗
20. Targeting lentiviral vectors to specific cell types in vivo10.1073/pnas.0604993103 ↗
21. Generation of targeted retroviral vectors by using single-chain variable fragment: an approach to in vivo gene delivery10.1073/pnas.92.16.7570 ↗
22. Polybrene increases retrovirus gene transfer efficiency by enhancing receptor-independent virus adsorption on target cell membranes10.1016/S0301-4622(02)00057-1 ↗
23. Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells10.1038/nm0896-876 ↗
24. Vectofusin-1 improves transduction of primary human cells with diverse retroviral and lentiviral pseudotypes, enabling robust, automated closed-system manufacturing10.1089/hum.2019.157 ↗
25. Bioinstructive implantable scaffolds for rapid in vivo manufacture and release of CAR-T cells10.1038/s41587-022-01245-x ↗
26. Inhibition of post-surgery tumour recurrence via a hydrogel releasing CAR-T cells and anti-PDL1-conjugated platelets10.1038/s41551-021-00712-1 ↗
27. Delivery of CAR-T cells in a transient injectable stimulatory hydrogel niche improves treatment of solid tumors10.1126/sciadv.abn8264 ↗
28. Biomaterials as Local Niches for Immunomodulation10.1021/acs.accounts.0c00341 ↗
29. Scaffold-mediated static transduction of T cells for CAR-T cell therapy10.1002/adhm.202000275 ↗
30. Fabrication and use of dry macroporous alginate scaffolds for viral transduction of T cells10.3791/64036 ↗
31. S. Pandit, P. Agarwalla, F. Song, A. Jansson, G. Dotti, Y. Brudno, Implantable car T cell factories enhance solid tumor treatment, (2023). 10.2139/ssrn.4648848.10.2139/ssrn.4648848 ↗
32. Novel alginate sponges for cell culture and transplantation10.1016/S0142-9612(96)00181-0 ↗
33. Structural basis for the recognition of LDL-receptor family members by VSV glycoprotein10.1038/s41467-018-03432-4 ↗
34. Absorption rate governs cell transduction in dry macroporous scaffolds10.1039/D2BM01753A ↗
35. Understanding restriction factors and intrinsic immunity: insights and lessons from the primate lentiviruses10.2217/fvl.14.25 ↗
36. Understanding and altering cell tropism of vesicular stomatitis virus10.1016/j.virusres.2013.06.003 ↗
37. Silencing and variegation of gammaretrovirus and Lentivirus vectors, Hum10.1089/hum.2005.16.1241 ↗
38. Dose-response correlation for CAR-T cells: a systematic review of clinical studies10.1136/jitc-2022-005678 ↗
39. Clinical use of lentiviral vectors10.1038/s41375-018-0106-0 ↗
40. In vivo generation of CAR T cells in the presence of human myeloid cells10.1016/j.omtm.2022.06.004 ↗
41. Establishment of a simple and efficient platform for car-t cell generation and expansion: from lentiviral production to in vivo studies10.1016/j.htct.2019.06.007 ↗
42. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias10.1182/blood-2011-04-348540 ↗